Predicta Biosciences is a precision oncology company integrating cutting edge multiomics and liquid biopsies to develop innovative diagnostic and therapeutic products. Predicta's diagnostic product portfolio removes the burden of bone-marrow biopsies, through small blood-based samples, and enables best-in-class treatment decision-making for immunotherapies. Utilizing the data from the diagnostic platform, Predicta has an in-house therapeutic pipeline of novel immunotherapy targets in pre-clinical discovery and development.
Total raised: $5.2M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.07.2024 | Seed | $5.2M | - |
Mentions in press and media 4
| Date | Title | Description |
| 29.07.2024 | Predicta Biosciences: Pioneering a New Era in Cancer Diagnostics | Predicta Biosciences is making waves in the ocean of cancer diagnostics. With a fresh infusion of $5.2 million in seed funding, this Boston-based precision oncology company is poised to change the landscape of how we detect and treat blood ... |
| 27.07.2024 | Predicta Biosciences Raises $5.2 Million To Develop Novel Diagnostic And Therapeutic Products | Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic products, announced it had raised an oversubscribed $5.2 million seed round led by The Engine Ventures. And additional participating investors in... |
| 16.07.2024 | Predicta Biosciences Raises $5.2M in Seed Funding | Predicta Biosciences team (Photo: Business Wire) Predicta Biosciences, a Boston, MA-based precision oncology company developing diagnostic and therapeutic products, raised $5.2M in Seed funding. The round was led by The Engine Ventures, wit... |
| - | Predicta Biosciences | “Home | Predicta Biosciences” |